Non-Invasive Prenatal Testing Market Can Surpass a Valuation of $8,217.53 Mn by 2025 | Covid19 Impact on Non-Invasive Prenatal Testing Industry

Non-Invasive Prenatal Testing Market Can Surpass a Valuation of $8,217.53 Mn by 2025 | Covid19 Impact on Non-Invasive Prenatal Testing Industry
Market Report Titled ” Non-Invasive Prenatal Testing Industry Research Report – Forecast to 2025″ is a Specialist Examination Report Explores the Market by Research Methodology, Covid19 Impact, Segmentation, Key Players, and Major Region Globally .

Non-Invasive Prenatal Testing Market Overview:

The global study on the non-invasive prenatal testing market reveals various opportunities that can take the market ahead with a CAGR of 12.8% during the forecast period of 2019 to 2025. Market Research Future (MRFR) identifies the rising level of awareness related to such procedures, adoption of unhealthy lifestyle, booming population, and technical progress as major factors that can boost the market growth. 


To learn more about the global trends impacting the future of market research, download a free sample:    

However, the market may find obstacles in the shape of the availability of alternative techniques and less accuracy in testing as major drawbacks for the global market. 


Non-Invasive Prenatal Testing Market Segmentation: 

The global market for the non-invasive prenatal testing market has been segmented by MRFR experts into product type, technique, application, and end user to glean in more insights and impact various strategic deals.  

By product type, the global market has been segmented into devices, consumables, and others. The devices segment includes ultrasound devices, polymerase chain reaction instruments, microarrays, sequencing systems, and others.  

By technique, the market has been segmented into biochemical screening tests and ultrasound detection. Among these, the biochemical screening tests segment has a major market share. This is primarily due to the rising cases of diabetes, which is boosting global demand.  

By application, the global market study encompasses trisoy, microdeletion syndrome, and others. The trisomy segment has the largest market share and it is getting traction from the trisomy-related disorders. 

By end users, the global market includes diagnostic centers, hospitals & surgical centers, and others. The diagnostic centers are the leading market segment as it serves as the primary diagnostic point for such a detailed process. 

 Non-Invasive Prenatal Testing Market Regional Analysis: 

The Americas is using the technological advantage and investment capacity as prime factors to lead the global market. The US holds the maximum market share as its infrastructural scope allows the market to expand more freely. Similar traits can be witnessed in Europe, where countries like Italy, France, the UK, Germany, and others are investing more in the healthcare sector to further promote this market. 


Non-Invasive Prenatal Testing Market Competitive Landscape:

 Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), General Electric Company [GE Healthcare] (US), Beijing Genomics Institute (China), Tarsa Therapeutics, Inc. (US), Perkinelmer, Inc. (US), PhytoHealth Corporation (Taiwan), Hoffman-La Roche Ltd. (Switzerland), Laboratory Corporation of America Holdings (US), Centogene Holding AG (Germany), Natera, Inc. (US), and Yourgene Health (UK), are companies that are known for making impacts on the global non-invasive prenatal testing market through various strategic implementations. These companies are making profits using strategic measures like mergers, acquisitions, collaborations, innovations, and others as their supportive hands. Increasing the research and development funding is another measure that boosts innovation and impacts launching and branding tactics. 

Industry News:

A recent article published in BJOG by researchers from the Center for Medical Genetics, School of Life Sciences, Central South University in China revealed that the primary tests of the novel noninvasive prenatal diagnosis (NIPD) assay for β-thalassemia is showing positive results. The process, according to the test, is highly reliable and accurate and, if optimized, could be a perfect alternative for traditional invasive prenatal diagnosis (IPD) that has a connection with carriers of pathogenic HBB variants with pregnancy.


The non-invasive prenatal testing process can find better acceptance with the outbreak of the COVID-19 pandemic. This is due to the growing instances where the newly born babies were detected with COVID-19. Certainly, this would increase the demand for tests that can secure the well-being of a baby.


Obtain Premium Research Report Details, Considering the impact of COVID-19 @

Related Report Available:

Surgical Scalpel Market Research Report: By Product (Disposable, Reusable Surgical Scalpel, & Accessories), Material Type (Stainless, High-Grade Carbon Steel), Application (Bariatric, Cardiovascular Surgeries), End User — Global Forecast till 2023: 

Opioids Market Information: By Product (Extended-Release/Long-Acting Opioid, Immediate Release/Short Acting Opioid), by Application (Pain Relief, Anesthesia, Cough Suppression, Deaddiction, Others), by End User, and by Region — Global Forecast till 2023:


About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India